Companies are busy developing combination therapies combining the latest diabetes treatment, SGLT-2 inhibitors, with existing diabetes treatment. In particular, domestic companies that are eyeing the SGLT-2 market have been testing various combinations for commercialization.

On the 26th, the Ministry of Food and Drug Safety approved the Phase III clinical trial protocol for ‘JT-001’ that was submitted by Jeil Pharmaceutical. The trial will be conducted to assess the safety and efficacy of additionally administering JT-001 in combination with dapagliflozin+metformin in type 2 diabetes patients inadequately controlled by the dapagliflozin+metformin combination.

JT-001, or pioglitazone hy